Author:
Niglio Scot A.,Jia Rachel,Ji Jiayi,Ruder Samuel,Patel Vaibhav G.,Martini Alberto,Sfakianos John P.,Marqueen Kathryn E.,Waingankar Nikhil,Mehrazin Reza,Wiklund Peter,Oh William K.,Mazumdar Madhu,Ferket Bart S.,Galsky Matthew D.
Reference37 articles.
1. Cancer stat facts: bladder cancer;National Cancer Institute Surveillance Epidemiology and End Results Program,2018
2. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J Clin Oncol,2012
3. Molecular biology and targeted therapies for urothelial carcinoma;Seront;Cancer Treat Rev,2015
4. European Commission. Union Register of medicinal products for human use: pembrolizumab, KEYTRUDA. http://ec.europa.eu/health/documents/community-register/html/h1024.htm.
5. European Commission. Union Register of medicinal products for human use: Atezolizumab, Tecentriq. http://ec.europa.eu/health/documents/community-register/html/h1220.htm.